Clinical Trial

Trial of Efficacy and Safety of NS-229 Versus Placebo in Patients With Eosinophilic Granulomatosis With Polyangiitis

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study will enroll male and female subjects who are 18 years of age or older with Eosinophilic Granulomatosis With Polyangiitis.
Protocol Amendment History 3 changes
critical Trial status changed: Recruiting → Active, Not Recruiting 2026-05-27
notable Primary completion pushed: 2026-06 -> 2026-12 2026-05-27
minor Completion pushed: 2026-07 -> 2026-12 2026-05-27
Trial Details
NCT Number NCT06046222
Lead Sponsor NS Pharma, Inc.
Collaborators: Nippon Shinyaku Co., Ltd.
Conditions Eosinophilic Granulomatosis With Polyangiitis, Churg-Strauss Syndrome
Enrollment 45 participants
Start Date 2023-12-20
Primary Completion 2026-12 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2026-05-26